Outcome and patterns of failure in testicular lymphoma: a multicenter rare cancer network study

Zouhair, Abderrahim; Weber, Damien Charles; Belkacémi, Yazid; Ketterer, Nicolas; Dietrich, Pierre Yves; Villà, Salvador; Scandolaro, Luciano; Bieri, Sabine; Studer, Gabriela; Delacrétaz, F; Girardet, Christophe; Mirimanoff, R.O.; Ozşahin, Mahmut

doi:10.1016/s0360-3016(01)02647-5

Cited by 56 publications

(30 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specifically, the frequency of post-GCB DLBCL, which is more often treatment resistant, is higher in immunedepleted patients, and multiple studies have shown a relationship between lymphoma pathobiology and central nervous system involvement. 33,40,41 Notably, three-quarters of our patients who developed central nervous system involvement also had low CD4 ϩ cell counts, indicating a major overlap between these 2 prognostic factors. These results suggest that tumor pathobiology at the time of clinical presentation is the important determinant of clinical outcome, consistent with recent findings in HIV-negative DLBCL, and not the immune environment during treatment.…”

Section: Discussionmentioning

confidence: 79%

Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology

Little

Pittaluga

Grant

et al. 2003

Blood

328

256

View full text Add to dashboard Cite

The outcome of acquired immunodeficiency syndrome-related lymphomas (ARLs) has improved since the era of highly active antiretroviral therapy, but median survival remains low. We studied dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) with suspension of antiretroviral therapy in 39 newly diagnosed ARLs and examined protein expression profiles associated with drug resistance and histogenesis, patient immunity, and HIV dynamics and mutations. The expression profiles from a subset of ARL cases were also compared with a matched group of similarly treated HIV-negative cases. Complete remission was achieved in 74% of patients, and at 53 months median follow-up, disease-free and overall survival are 92% and 60%, respectively. Following reinstitution of antiretroviral therapy after chemotherapy, the CD4 ؉ cells recovered by 12 months and the viral loads decreased below baseline by 3 months. Compared with HIV-negative cases, the ARL cases had lower bcl-2 and higher CD10 expression, consistent with a germinal center origin and good prognosis, but were more likely to be highly proliferative and to express p53, adverse features with standard chemotherapy. Unlike HIV-negative cases, p53 overexpression was not associated with a poor outcome, suggesting different pathogenesis.

show abstract

Section: Discussionmentioning

confidence: 79%

Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology

Little

Pittaluga

Grant

et al. 2003

Blood

328

256

View full text Add to dashboard Cite

show abstract

“…21 Younger age and early stage, which are part of the IPI, have been shown to be independent prognostic factors influencing the overall and disease-free survival. 10 The first diagnostic and therapeutic procedure performed in testicular lymphoma cases is orchiectomy, 11 which was performed in all cases in our series. Further optimal treatment is unclear because of the rarity of this disease, and because there are very few prospective studies 2,8 and no randomized studies.…”

Section: Discussionmentioning

confidence: 87%

“…4 Due to the small number of cases of primary testicular lymphoma, there are few prospective treatment trials. 2,8 Retrospective studies report treatment with orchiectomy, various forms of chemotherapy and/or radiation, 3,6,7,[9][10][11][12][13][14] with some cases including prophylactic radiation and/or intrathecal chemotherapy. Testicular lymphoma shows a propensity towards systemic dissemination and relapse even years after complete response (CR) to treatment.…”

Section: Introductionmentioning

confidence: 99%

Malignant lymphoma of the testis: a study of 12 cases

Lantz

Power

Hutton³

et al. 2013

CUAJ

View full text Add to dashboard Cite

Introduction: Testicular lymphoma is a rare and deadly disease representing 1% to 2% of all non-Hodgkin lymphomas (NHLs) and approximately 5% of all testicular neoplasms. Our objective is this study was to identify the presenting signs and symptoms, treatment and outcome of patients with testicular lymphoma diagnosed at our institution from 1992 to 2005, and to identify any differences in survival based on Ann Arbor Stage and International Prognostic Index (IPI). Methods:A retrospective chart review was performed to identify demographic characteristics, presenting signs and symptoms, treatment and outcomes. Survival was assessed using Kaplan-Meier survival curves and log-rank testing.

show abstract

“…For patients with testicular lymphoma, a high relapse rate in the CNS and contralateral testis has been well documented [12,22,28,29,30,31,32,33]. Most recent literature has confirmed the benefit of prophylactic RT to the contralateral testis [13,14,16,20,29,31,32,34].…”

Section: Discussionmentioning

confidence: 99%

Clinical Features of Testicular Lymphoma

Shih

Chang

et al. 2013

Acta Haematol

View full text Add to dashboard Cite

Testicular lymphoma is a rare condition, so large scale prospective studies are difficult to conduct. Consensus regarding standard treatment is lacking. This study retrospectively reviewed 22 patients with testicular lymphoma. One patient with diffuse large B-cell lymphoma (DLBCL) was lost to follow-up after diagnosis. Two patients with Burkitt's lymphoma had poor outcomes regardless of treatment. Thus, we analyzed the clinical features, treatments, and outcomes of 19 patients with DLBCL. The median progression-free and overall survival was 28.3 and 36.3 months, respectively. A good response to treatment was a favorable prognostic factor. Because of the high relapse rate, the outcome is poor for testicular lymphoma. Therefore, long-term follow-up is strongly recommended.

show abstract

Outcome and patterns of failure in testicular lymphoma: a multicenter rare cancer network study

Cited by 56 publications

References 24 publications

Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology

Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology

Malignant lymphoma of the testis: a study of 12 cases

Clinical Features of Testicular Lymphoma

Contact Info

Product

Resources

About